Breyanzi Interactions
There are 298 drugs known to interact with Breyanzi (lisocabtagene maraleucel), along with 2 disease interactions. Of the total drug interactions, 69 are major, 214 are moderate, and 15 are minor.
- View all 298 medications that may interact with Breyanzi
- View Breyanzi disease interactions (2)
Most frequently checked interactions
View interaction reports for Breyanzi (lisocabtagene maraleucel) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Addyi (flibanserin)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- Alhemo (concizumab)
- alprazolam
- Altuviiio (antihemophilic factor)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- Andembry (garadacimab)
- AndroGel (testosterone)
- apremilast
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blenrep (belantamab mafodotin)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Brilinta (ticagrelor)
- Brineura (cerliponase alfa)
Breyanzi disease interactions
There are 2 disease interactions with Breyanzi (lisocabtagene maraleucel) which include:
More about Breyanzi (lisocabtagene maraleucel)
- Breyanzi consumer information
- Compare alternatives
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rituxan
Rituxan is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as ...
Monjuvi
Monjuvi is used to treat diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Kymriah
Kymriah is used to treat B-cell precursor acute lymphoblastic leukemia (ALL), large B-cell ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma (FL) in adults. It is a p ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Tazverik
Tazverik (tazemetostat) used for the treatment of patients with epithelioid sarcoma and follicular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.